Introduction
Febrile seizures (FS) are the most common form of childhood seizures, usually appearing between 6 months and 6 years of age. 1 They are benign and affect about 2-5% of all children, and recurrences are common. 2 The pathomechanisms of FSs are not known. Since Na+ channel disorders, in which FSs are seen together with generalized epilepsy (GEFS+), resemble FSs, it has been hypothesized that FSs are transient ion channel disorders which are dependent on the developmental stage of the brain. 3 The S100 proteins, of which there are more than 20, form the largest group of EF-hand Ca 2+ -binding proteins. They are regulatory and are tissue and cell-specific. Concentrations of S100B proteins correlate with the severity of brain damage and with the outcome after brain injury. 4 Elevated S100B levels are detected as a marker of injury to the astrocytes even after mild head injury, 5 in children with septic encephalopathy and in newborns after prolonged labour, 6 and they are also associated with a number of other diseases, e.g. migraine, epilepsy, cardiomyopathy, cancer and inflammatory and autoimmune diseases. 7 We hypothesized that S100B proteins may give an indication of an ongoing pathological process in the brain connected with FS and could be predictive of recurrences of FSs. We measured the concentrations of these proteins in children who had had their first FS and control children with febrile infections but without seizures, comparing serum concentrations between the patients and controls and correlating them with the severity of FSs and its recurrences.
Materials and methods
The basic population consisted of the 231 patients at the Department of Pediatrics, University of Oulu who had experienced their first FS and had participated in our previous evaluation of the efficacy of antipyretics for preventing recurrences during the period 1997-2003. 8 The study was performed according to the Keywords: S100B Febrile seizure Children A B S T R A C T S100B protein concentrations correlate with the severity and outcome of brain damage after brain injuries, and have been shown to be markers of blood-brain barrier damage. In children elevated S100B values are seen as a marker of damage to astrocytes even after mild head injuries. S100B proteins may also give an indication of an ongoing pathological process in the brain with respect to febrile seizures (FS) and the likelihood of their recurrence. To evaluate this, we measured S100B protein concentrations in serum and cerebrospinal fluid from 103 children after their first FS. 33 children with acute infection without FS served as controls for the serum concentrations. In the FS patients the mean S100B concentration in the cerebrospinal fluid samples was 0.21 mg/L and that in the serum samples 0.12 mg/L. The mean serum concentration in the controls was 0.11 mg/L (difference 0.01 mg/L, 95% confidence interval À0.02 to 0.04 mg/L, P = 0.46). There was a correlation between age and serum S100B concentration (r = À0.28, P = 0.008) in children under four years, but S100B concentrations did not predict the clinical severity of the FS nor their recurrence. There was no correlation between time of arrival at the hospital after FS and S100B concentration in serum (r = À0.130, P = 0.28) or in cerebrospinal fluid samples (r = À0.091, P = 0.52). Our findings indicate that FS does not cause significant blood-brain barrier openings, and increase the evidence that these seizures are relatively harmless for the developing brain. ß 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
had recurrences of FS (Table 1) . FS was considered complex when it was focal or prolonged (>15 min), or more than one seizure had occurred within 24 h. Parents were instructed to measure temperature and to record all seizures in detail. Nurses working within the study contacted the families by telephone at least once a month for two years to ensure that we received all the information needed. 8 Only data on patients with at least one febrile episode after their first FS (n = 66) were analysed with regard to the recurrence of FSs. The median time elapsing between the first FS episode and arrival at the hospital had been 2.4 h (range 0.08-73 h). Only 4 patients had arrived at hospital after an interval of 15 h. Blood samples were collected as soon as possible after arrival and the time delay was similar for all the patients, although the exact times of blood sampling are not available.
Assays
S100B was analysed using a fully automated LIAISON system (AB DiaSorin, Bromma, Sweden), an immunoluminometric assay which detects the b subunit of the S100 protein. The analytical sensitivity of this method is 0.013 lg/l, the typical intra-assay precision is below 5% and the inter-assay precision is below 10%.
Statistics
An unpaired t test was used to analyse differences in continuous variables between the two groups. Univariate associations between continuous variables were calculated using Pearson's rank correlation coefficients (r). All the data were analysed with SPSS, version 17.0, for Windows.
Results
The mean serum concentration of S100B protein was 0.12 mg/L among the patients with FS and 0.11 mg/L in the controls (difference 0.01, 95% confidence interval (CI) À0.02 to 0.04 mg/L, P = 0.46). The mean S100B value in the CSF of the patients with FS was 0.21 mg/L. The ratio between the mean CSF and serum S100B concentrations in patients with FS was 1.75.
There were no significant differences in mean serum or CSF S100B concentrations between the genders, between the patients with simple and complex FS, between the patients with and without a family history of FS, or between the patients with recurrent FS and those with no recurrences ( Table 2 ). The serum S100B concentration among the patients with complex FS was 0.10 mg/L in those with recurrent FS and 0.12 mg/L in those with no recurrence (difference À0.03 mg/L, 95% CI À0.1 to 0.05 mg/L, P = 0.44), The S100B concentrations in the CSF of the same patient groups were 0.24 mg/L and 0.20 mg/L, respectively (difference À0.04, 95% CI À0.30 to 0.21, P = 0.72).
The correlation between the patient's age and serum S100B concentration was significant (n = 91, r = À0.28, P = 0.008), but no such correlation was found in the CSF samples (n = 74, r = 0.001, P = 0.99) (Fig. 1) . There was no correlation between time of arrival at the hospital after FS and S100B concentration in either the serum (r = À0.130, P = 0.28) or the CSF samples (r = À0.091, P = 0.52).
Discussion
The children with FSs in this series did not have elevated serum S100B values, and the concentration of S100B proteins did not correlate with the severity of FS, nor did it predict recurrences of the seizures. Serum S100B protein concentrations decreased with age, as previously reported among healthy pediatric patients under the age of 7 years. 7, 9 S100 protein values in serum and CSF have previously been reported to be of the same magnitude among adult patients with recent non-complicated tonic-clonic seizures and controls, 7, 10 although the absolute CSF concentrations of S100 proteins were higher than in the present series and the mean serum values slightly lower. This may be attributable to the difference in age between the subjects. There are no valid reference values for the S100B concentration in the CSF of children, but the ratio between CSF and serum S100B concentrations in adults has been reported previously to be 40 in healthy controls, 10 63 in patients with epilepsy 10 and 164 in patients with traumatic brain injury. 11 The corresponding ratio between the mean CSF and serum S100B concentrations in our series of children was much lower than those reported in adults, indicating that the children with FS did not have elevated CSF S100B values. This expected ratio is extrapolated from adults, of course, and it should be noted that potential differences may exist for children. High concentrations of extracellular S100 proteins have been associated with the activation of cell metabolism, cell death and disease. An increased concentration of S100B is a feasible indicator of brain damage, 12 even after mild head injury, 7 and S100B protein is also a relevant marker of blood-brain barrier (BBB) openings. 13 BBB pathology has frequently been found following mild traumatic brain injury, and lasting BBB breakdown has been noticed with increased frequency and extent in patients with posttraumatic epilepsy. 14 Recent studies have indicated a critical role for opening of the BBB in the pathogenesis of posttraumatic epilepsy, 14, 15 since BBB disruption may lead to cortical dysfunction. S100B protein acts locally in the brain, however, and its short serum half-life, only approximately 25-113 min, poses challenges for its measurement. One limitation of this study is the possibility of a temporary small rise in S100B that may not be detectable any longer by the time of sampling. However, S100B values measured after brain injury are many times higher than those found here after FSs, 7 even with similar delays between the event and hospitalization. There was no correlation between time of arrival at the hospital and S100B concentration in the serum or CSF of our patients. In fact there are suggestions in the recent literature that later blood sampling may even be more specific for brain injury, since S100B also has extracranial sources, e.g. bone marrow, and these also peak in the early period after traumatic injury. 7 It should be remembered, of course, that our clinical samples for S100B measurement in children were taken from serum and CSF samples but not directly from the brain. If abnormally high tissue-specific protein S100B levels were to exist in the brain, pathological levels of these proteins would show up in the serum and CSF as well. As it was, the S100B protein concentrations did not have any clinical prognostic value for assessing the severity of FS or the likelihood of a recurrence. The reason for a correlation between serum S100B concentration and age, but not between CSF S100B concentration and age is not known, but the effects of extracranial sources of S100B might be a possible explanation. All our patients were under four years of age, and this finding needs to be tailored to that population, especially when no significant correlation exists between age and serum S100B levels in adults.
Our patients with FS had similar concentrations of S100B to the control children, indicating that a FS does not cause significant BBB openings, and increasing the evidence that these seizures are relatively harmless for the developing brain.
